hotspot -WSS

hotspot

author：comprehensive 2025-09-28 23:24:28 - browse：42

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： John Green on his newest strategy for fighting tuberculosis

WSS

STAT wants to know your pick for a great summer read or listen

Ebola: Gilead Sciences antiviral shows promise as new treatment

Prescription digital therapeutics are key to pharma’s future

UpToDate has a racism problem: Dr. Stanley Goldfarb

John Green on his newest strategy for fighting tuberculosis

How many hemophilia patients actually want gene therapy?

entertainment

hotspot

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

What affirmative action's end means to a medical student

Peter Hotez and the public health issue of online harassment

Being 'nonadherent' patient made me a more empathetic doctor

23andMe had bad news about my health. I wish a person had delivered it

Why scientists need input from humanists on sensitive research

The high cost of giving birth even with insurance

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

The high cost of giving birth even with insurance

Canadians with cystic fibrosis outlive Americans by a decade

focus

President Biden's budget: Here's what you might have missed

'Screen and refer' systems are hurting patients

HHS secretary Becerra pressed on Change HealthCare cyberattack

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

UpToDate has a racism problem: Dr. Stanley Goldfarb

UpToDate has a racism problem: Dr. Stanley Goldfarb

focus

entertainment

knowledge

focus